When CRISPR-Cas9 first gained attention, it was hailed as a game-changer for gene editing. But recent developments reveal that CRISPR is also revolutionizing the field of molecular diagnostics.

Two CRISPR-based systems—SHERLOCK (Specific High Sensitivity Enzymatic Reporter Unlocking) and DETECTR (DNA Endonuclease Targeted CRISPR Trans Reporter)—are enabling rapid, accurate, and low-cost detection of genetic material. Unlike traditional PCR tests that require thermal cycling and lab infrastructure, CRISPR diagnostics are:

• Fast: Results in under an hour.
• Portable: Effective even in resource-limited settings.
• Versatile: Can detect viruses (e.g., Zika, SARS-CoV-2), bacteria, or even cancer mutations.

In one landmark application, SHERLOCK was used to detect the Omicron variant of COVID-19 using paper-based strips and a mobile phone reader, with >95% accuracy.

Beyond disease detection, researchers are exploring CRISPR’s integration into:

• Wearable biosensors for real-time health tracking.
• Multiplexed testing where dozens of targets can be screened simultaneously.
• Environmental monitoring, such as detecting pathogens in food and water.

CRISPR diagnostics embody the future of personalized medicine—affordable, accessible, and adaptable.